TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.
Ghisoni E, Maggiorotto F, Borella F, Mittica G, Genta S, Giannone G, Katsaros D, Sciarrillo A, Ferrero A, Sarotto I, Erriquez J, Di Renzo MF, Aglietta M, Valabrega G.
Ghisoni E, et al. Among authors: genta s.
J Ovarian Res. 2019 Feb 13;12(1):17. doi: 10.1186/s13048-019-0492-6.
J Ovarian Res. 2019.
PMID: 30760286
Free PMC article.